Ovarian Cancer

Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.

Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.

Linda R. Duska, MD, discusses neoadjuvant chemotherapy versus upfront surgical debulking in patients with advanced ovarian cancer.

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.

At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.

Madeleine B. Courtney Brooks, MD, MPH, sheds light on the current treatment paradigm of recurrent ovarian cancer.

Brian Orr, MD, discusses the challenges with immunotherapy in ovarian cancer treatment while pointing to early promising data with combination regimens.

John Comerci, Jr, MD, provides an overview of advances made in ovarian cancer and remaining challenges to address with future research.

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Combining olaparib with standard bevacizumab significantly improved progression-free survival compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

Michelle M. Boisen, MD, discusses the role of neoadjuvant chemotherapy in advanced ovarian cancer and data comparing outcomes with this modality versus upfront surgery.

Mian M. Shahzad, MD, PhD, discusses the use of checkpoint inhibition in advanced ovarian cancer.

Jeannie Chern, MD, discusses developments with genetic testing in ovarian cancer and key trials in patients with recurrent disease.

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Mitchel Hoffman, MD, explains the use of surgery and neoadjuvant chemotherapy in ovarian cancer.

Hye Sook Chon, MD, discusses the progress of maintenance therapy in ovarian cancer.

Robert M. Wenham, MD, discusses frontline management strategies for patients with newly diagnosed advanced ovarian cancer as well as the complexities of maintenance therapy.